Infantile hemangioma ( HI ) is the most common children s vascular tumor . It is a benign tumor with essentially clinical diagnosis. Despite its benign character, treatment is required in many situations.
This is a retrospective study of 94 outpatients treated with propranolol and followed in the pediatric plastic surgery department (surgery C) at the Rabat Children's Hospital for a period of 4 years from, 2012 to 2017.
The average age of children treated was 3 months, with a female predominance (n = 60, 74%).
Tuberous HI was the most common clinical type (n = 68, 70.1%), the single form was predominant (n = 85, 90%), cervico-cephalic localization was the most common (n = 75, 72.1%), labial localization accounted for 40% (n = 30), 6 segmental HIs were reported (6.4%) including 3 PHACES syndromes including Dandy Walker syndrome. The average diameter of HI was 4cm.
Therapeutic indications were for : functional risk (n = 44, 43.5%), ulceration (n = 35, 43.5%), aesthetic risk (n = 20, 20%), and life risk (n = 35, 43.5%), the dosage was 3 mg / kg / day of propanolol . The average duration of treatment was 9 months, the tolerance was good. Only one case of malaise has been reported. Efficacy was very high with 79% success (excellent response (n = 22, 24%), good response (n = 52, 55%)
The follow-up after the end of the treatment did not objectify any recurrence.
Key words: hemangioma, benign tumor, child, evolution, abstention propranolol, benefit - risk, functional and vital prognosis
|
